Interplay of Tocilizumab in Critical COVID-19 Cases
Interplay of Tocilizumab in Critical COVID-19 Cases
ISSN: 2757-976X ;
E-ISSN: 2757-976X ;
- Year : 2023
- Vol : 3
- No : 2
- Page : 66-71
ÖZ
ABSTRACT
Aim: Tocilizumab (TCZ) has become a prominent antibody-based therapeutic option among treatment regimens during the Corona Virus 2019 (COVID-19) pandemic. This study aimed to evaluate laboratory changes, prognostic laboratory biomarkers, and the effects of the timing of TCZ application on mortality in COVID-19 patients who underwent TCZ.
Methods: This retrospective, sectional study was conducted with COVID-19 patients received additional TCZ-based treatment. TCZ was administered at a dose of 8 mg/kg/day. The patients' data were recruited from their follow-up records and the digital hospital information system.
Results: The data of 64 patients have been subjected to evaluation. The mean age of all patients was 62.43 ± 14.2. Half of the patients who placed in the intensive care unit had received invasive respiratory support. All patients had received favipiravir, hydroxychloroquine, and convalescent plasma-based therapy. The mean time of TCZ administration was 7 days after hospitalization. In general, ferritin and d-dimer levels stood out as prognostic biomarkers among the laboratory results, whereas in lymphopenic patients, the acute-phase reactants were favored. The presence of comorbidities was associated with an increase in hospital stay and mortality. Mortality was found to increase in patients who received early administration of TCZ.
Conclusion: Prognostic biomarkers previously addressed were also prominent in our study. Considering that early TCZ administration is deemed risky in the literature and may increase mortality, caution should be exercised in its early application.
Key words: COVID-19, disease severity, interleukin-6, mortality, tocilizumab
Aim: Tocilizumab (TCZ) has become a prominent antibody-based therapeutic option among treatment regimens during the Corona Virus 2019 (COVID-19) pandemic. This study aimed to evaluate laboratory changes, prognostic laboratory biomarkers, and the effects of the timing of TCZ application on mortality in COVID-19 patients who underwent TCZ.
Methods: This retrospective, sectional study was conducted with COVID-19 patients received additional TCZ-based treatment. TCZ was administered at a dose of 8 mg/kg/day. The patients' data were recruited from their follow-up records and the digital hospital information system.
Results: The data of 64 patients have been subjected to evaluation. The mean age of all patients was 62.43 ± 14.2. Half of the patients who placed in the intensive care unit had received invasive respiratory support. All patients had received favipiravir, hydroxychloroquine, and convalescent plasma-based therapy. The mean time of TCZ administration was 7 days after hospitalization. In general, ferritin and d-dimer levels stood out as prognostic biomarkers among the laboratory results, whereas in lymphopenic patients, the acute-phase reactants were favored. The presence of comorbidities was associated with an increase in hospital stay and mortality. Mortality was found to increase in patients who received early administration of TCZ.
Conclusion: Prognostic biomarkers previously addressed were also prominent in our study. Considering that early TCZ administration is deemed risky in the literature and may increase mortality, caution should be exercised in its early application.
Key words: COVID-19, disease severity, interleukin-6, mortality, tocilizumab
Correspondence Address :
Email : [email protected]
Cite this Article As : Akay Cizmecioglu H, Goktepe MH, Bayraktar HI, Cizmecioglu A. Interplay of Tocilizumab in Critical COVID-19 Cases. Mev Med Sci. 2023;3(2):66-71
Description : Yazarların hiçbiri, bu makalede bahsedilen herhangi bir ürün, aygıt veya ilaç ile ilgili maddi çıkar ilişkisine sahip değildir. Araştırma, herhangi bir dış organizasyon tarafından desteklenmedi.Yazarlar çalışmanın birincil verilerine tam erişim izni vermek ve derginin talep ettiği takdirde verileri incelemesine izin vermeyi kabul etmektedirler. None of the authors, any product mentioned in this article, does not have a material interest in the device or drug. Research, not supported by any external organization. grant full access to the primary data and, if requested by the magazine they agree to allow the examination of data.
Email : [email protected]
Cite this Article As : Akay Cizmecioglu H, Goktepe MH, Bayraktar HI, Cizmecioglu A. Interplay of Tocilizumab in Critical COVID-19 Cases. Mev Med Sci. 2023;3(2):66-71
Description : Yazarların hiçbiri, bu makalede bahsedilen herhangi bir ürün, aygıt veya ilaç ile ilgili maddi çıkar ilişkisine sahip değildir. Araştırma, herhangi bir dış organizasyon tarafından desteklenmedi.Yazarlar çalışmanın birincil verilerine tam erişim izni vermek ve derginin talep ettiği takdirde verileri incelemesine izin vermeyi kabul etmektedirler. None of the authors, any product mentioned in this article, does not have a material interest in the device or drug. Research, not supported by any external organization. grant full access to the primary data and, if requested by the magazine they agree to allow the examination of data.
Interplay of Tocilizumab in Critical COVID-19 Cases, strArastirmaMakalesi,
2023, Vol. 3 (2)
2023, Vol. 3 (2)
Received :11.04.2023,
Accepted : 07.08.2023,
Published Online : 15.08.2023
Mevlana Medical Sciences Journal
ISSN: 2757-976X ;
E-ISSN: 2757-976X ;
-
strArastirmaMakalesi
-
View as PDF -
Keywords
covıd-19, disease severity, ınterleukin-6, mortality, tocilizumab